MedTrace Logo

Nicotinic Receptors and Schizophrenia

NCT00952393 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-02-05

Study results available
· View outcomes & findings →

Summary

The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.

Conditions

Interventions

DRUG

Pharmacokinetic

Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Robert Freedman, MD · VA Eastern Colorado Health Care System, Denver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952393 on ClinicalTrials.gov